Clinical trials: Locally Advanced Gastric Adenocarcinoma
Gastric Cancer, Gastro Esophageal Junction Cancer
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
For locally advanced gastric and gastroesophageal junction adenocarcinoma (cT3-4bNanyM0), perioperative PD-1 antibody combined with chemotherapy can downstage tumor stage, increase the R0 resection rate, and may improve the…
- Trial name
- NCT06447636
- Testing
- Surufatinib, Sintilimab, Oxaliplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Gastric Junction Adenocarcinoma, Gastric Cancer
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
The goal of this clinical trial is to learn if sorbitol works to enhance the therapeutic effect of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer.
- Conditions
- Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy, Neoadjuvant Therapies
- Trial name
- SNCCTGC (NCT06826079)
- Testing
- Sorbitol + PD-1 inhibitor + SOX chemotherapy, PD-1 inhibitor + SOX chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric (Stomach) Cancer, Gastric Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic…
- Conditions
- Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
- Trial name
- NCT06871527
- Testing
- fruquintinib + tislelizumab + FOLFOX
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative fruquintinib combined with sintilimab and SOX is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT07658872
- Testing
- fruquintinib + sintilimab + SOX, Sinitilimab+SOX
- Volunteers
- 120 people
- Sponsor
- Sichuan University
Uterine Cervical Neoplasms, Surgery
Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
This study aims to collect data of patients with Gastric-type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of Gastric-type Endocervical Adenocarcinoma, and…
- Conditions
- Uterine Cervical Neoplasms, Surgery, Therapy, Locally Advanced Cervical Carcinoma
- Trial name
- NCT06897306
- Testing
- surgery
- Where
- China
- Volunteers
- 317 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastric Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if surgery alone or surgery combined with chemotherapy is more effective in treating…
- Trial name
- NCT00004099
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Where
- 18 sites in Belgium, Egypt and 3 more
- Volunteers
- 144 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
HER2-positive, Locally Advanced Solid Tumor
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
The SOX regimen has became the standard perioperative chemotherapy for locally advanced gastric cancer; The immune checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer；For HER2-positive…
- Conditions
- HER2-positive, Locally Advanced Solid Tumor, Immunotherapy, Sintilimab
- Trial name
- NCT05218148
- Testing
- sintilimab, Trastuzumab, S-1 plus oxaliplatin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Aiping Zhou
Gastric / Gastroesophageal Junction Adenocarcinoma
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
Standard treatment for locally advanced gastric cancer currently involves surgery combined with chemotherapy administered both before and after the operation.
- Trial name
- MRD-ATLAS (NCT07257380)
- Testing
- Standard neoadjuvant therapy, Radical gastrectomy, Standard adjuvant therapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric Cancer Stage III
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
The goal of this clinical trial is to learn if Omega-3 fatty acids supplementation can enhance the efficacy of neoadjuvant immunotherapy in patients with locally advanced gastric and gastroesophageal junction adenocarcinoma.
- Trial name
- NCT07050524
- Testing
- Omega-3 Supplementation, Neoadjuvant Immunotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer).
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- MOUNTAINEER-02 (NCT04499924)
- Testing
- tucatinib, trastuzumab, ramucirumab
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 17 people
- Sponsor
- Seagen Inc.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally…
- Trial name
- NCT03281369
- Testing
- 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 219 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Gastric Adenocarcinoma
Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
This interventional prospective randomized controlled study was conducted to compare the effects of high-protein oral nutritional supplement (ONS) and medical nutritional therapy to medical nutrition therapy alone on nutritional…
- Trial name
- NCT06645912
- Testing
- oral nutritional supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital
Gastric Adenocarcinoma
Multimodal Model Predicts Recurrence
This study focuses on developing an advanced model that combines clinical information, imaging, and pathology data to predict the likelihood of cancer returning after surgery in patients with locally advanced gastric cancer.
- Trial name
- FUTURE12 (NCT06690268)
- Testing
- Multimodal AI-driven predictive model
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Qun Zhao
Gastric Cancer, Gastric Adenocarcinoma
Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer
This study investigates the prognostic role of liquid biopsy in patients with locally advanced gastric cancer. Liquid biopsy for the detection of circulating tumor DNA will be performed: In the peritoneal lavage, during staging…
- Trial name
- LIQUID (NCT04943406)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Gastric Cancer
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
This study is a phase II, prospective, single-center, single-arm trial to evaluate the efficacy and safety of the combination of neoadjuvant transcatheter arterial chemoembolization (TACE) and PD-1 antibody Tislelizumab in the…
- Trial name
- NCT04799548
- Testing
- Transcatheter Arterial Chemoembolization, Tislelizumab
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Zhongshan Hospital
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
This is a multicenter, open-label, single arm phase II study to evaluate the efficacy and safety of Infigratinib in patients with locally advanced or metastatic GC or GEJ patient with FGFR2 gene amplification, who have failed at…
- Trial name
- NCT06206278
- Testing
- Infigratinib
- Where
- 30 sites in China
- Volunteers
- 6 people
- Sponsor
- LianBio LLC
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a multicenter, open-label, phase II clinical study to explore the safety and efficacy of BL-M07D1+PD-1 monoclonal antibody in patients with unresectable locally advanced or metastatic HER2-positive gastric or…
- Trial name
- NCT06423885
- Testing
- BL-M07D1, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.